Answer
Ibrutinib (Imbruvica) has a minor influence on driving and machinery use, with reported fatigue, dizziness and asthenia requiring consideration when assessing a patient's ability to perform these activities.
Sources for this answer
- IMBRUVICA 140 mg film-coated tablets (Great Britain)Janssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §4.7 Effects on ability to drive and use machines · Version 25Document updated
Sources checked